Ferguson Wellman Capital Management Inc. increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 208,173 shares of the medical research company’s stock after buying an additional 1,253 shares during the quarter. Amgen makes up 1.6% of Ferguson Wellman Capital Management Inc.’s investment portfolio, making the stock its 17th largest holding. Ferguson Wellman Capital Management Inc.’s holdings in Amgen were worth $40,525,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. FMR LLC boosted its holdings in Amgen by 4.4% in the 3rd quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock valued at $7,425,805,000 after purchasing an additional 1,505,266 shares during the period. Capital International Investors boosted its holdings in Amgen by 301.4% in the 3rd quarter. Capital International Investors now owns 11,093,182 shares of the medical research company’s stock valued at $2,299,506,000 after purchasing an additional 8,329,861 shares during the period. Capital World Investors bought a new stake in Amgen in the 3rd quarter valued at $952,900,000. Renaissance Technologies LLC boosted its holdings in Amgen by 8.2% in the 3rd quarter. Renaissance Technologies LLC now owns 4,115,145 shares of the medical research company’s stock valued at $853,028,000 after purchasing an additional 311,545 shares during the period. Finally, Loomis Sayles & Co. L P boosted its holdings in Amgen by 1.8% in the 3rd quarter. Loomis Sayles & Co. L P now owns 3,452,206 shares of the medical research company’s stock valued at $715,608,000 after purchasing an additional 60,875 shares during the period. 76.86% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen stock opened at $203.88 on Friday. The stock has a market cap of $129.92 billion, a P/E ratio of 14.69, a PEG ratio of 2.04 and a beta of 1.32. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $210.19.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.45 by $0.24. The business had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the company posted $3.27 EPS. As a group, equities research analysts forecast that Amgen, Inc. will post 14.24 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a $1.45 dividend. This represents a $5.80 annualized dividend and a yield of 2.84%. The ex-dividend date is Thursday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
AMGN has been the subject of a number of recent research reports. Goldman Sachs Group restated a “buy” rating and issued a $229.00 price objective on shares of Amgen in a research note on Friday, October 12th. BidaskClub upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Wednesday, September 26th. restated a “buy” rating and issued a $224.00 price objective on shares of Amgen in a research note on Monday, October 1st. Jefferies Financial Group restated a “buy” rating and issued a $220.00 price objective on shares of Amgen in a research note on Monday, October 1st. Finally, Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research note on Monday, October 1st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $205.50.
In other Amgen news, Director Tyler Jacks sold 20,000 shares of the firm’s stock in a transaction dated Thursday, December 6th. The shares were sold at an average price of $195.41, for a total value of $3,908,200.00. Following the completion of the sale, the director now owns 28,979 shares in the company, valued at approximately $5,662,786.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Cynthia M. Patton sold 1,777 shares of the firm’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the sale, the senior vice president now owns 23,090 shares of the company’s stock, valued at approximately $4,684,499.20. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2019/01/20/amgen-inc-amgn-position-increased-by-ferguson-wellman-capital-management-inc.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: S&P 500 Index
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.